These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 32692903)
1. The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVID-19. Kow CS; Hasan SS Obesity (Silver Spring); 2020 Nov; 28(11):2035. PubMed ID: 32692903 [No Abstract] [Full Text] [Related]
2. Effect of angiotensin II blockers on the prognosis of COVID-19: a toxicological view. Shirazi FM; Banerji S; Nakhaee S; Mehrpour O Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):2001-2002. PubMed ID: 32557325 [No Abstract] [Full Text] [Related]
3. A potential protective role of losartan against coronavirus-induced lung damage. Zeinalian M; Salari-Jazi A; Jannesari A; Khanahmad H Infect Control Hosp Epidemiol; 2020 Jun; 41(6):752-753. PubMed ID: 32248854 [No Abstract] [Full Text] [Related]
4. RAAS blockers in hypertension posing a higher risk toward the COVID-19. Singh Y; Gupta G; Satija S; Negi P; Chellappan DK; Dua K Dermatol Ther; 2020 Jul; 33(4):e13501. PubMed ID: 32359088 [No Abstract] [Full Text] [Related]
5. Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19. Rothlin RP; Vetulli HM; Duarte M; Pelorosso FG Drug Dev Res; 2020 Nov; 81(7):768-770. PubMed ID: 32356926 [TBL] [Abstract][Full Text] [Related]
6. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Kreutz R; Algharably EAE; Azizi M; Dobrowolski P; Guzik T; Januszewicz A; Persu A; Prejbisz A; Riemer TG; Wang JG; Burnier M Cardiovasc Res; 2020 Aug; 116(10):1688-1699. PubMed ID: 32293003 [TBL] [Abstract][Full Text] [Related]
7. Renin-angiotensin system and SARS-CoV-2 interaction: underlying mechanisms and potential clinical implications. Hrenak J; Zorad S; Simko F Gen Physiol Biophys; 2020 May; 39(3):203-204. PubMed ID: 32525813 [TBL] [Abstract][Full Text] [Related]
8. Increased ACE2 Expression in Bronchial Epithelium of COPD Patients who are Overweight. Higham A; Singh D Obesity (Silver Spring); 2020 Sep; 28(9):1586-1589. PubMed ID: 32428380 [TBL] [Abstract][Full Text] [Related]
9. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial). Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D; Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924 [TBL] [Abstract][Full Text] [Related]
10. Time-critical administration of corticosteroid rescue therapy for COVID-19 pneumonitis in a ward-based patient with chronic obstructive pulmonary disease. Kuzeva A; Dost S; Lams B; Agarwal S; Furmedge DS Br J Hosp Med (Lond); 2020 Jul; 81(7):1-4. PubMed ID: 32730151 [No Abstract] [Full Text] [Related]
12. Covid-19 and COPD: A Personal Reflection. Russell R Int J Chron Obstruct Pulmon Dis; 2020; 15():883-884. PubMed ID: 32425514 [No Abstract] [Full Text] [Related]
13. Coronavirus Disease 2019 and Parkinsonism: A Non-post-encephalitic Case. Faber I; Brandão PRP; Menegatti F; de Carvalho Bispo DD; Maluf FB; Cardoso F Mov Disord; 2020 Oct; 35(10):1721-1722. PubMed ID: 32815213 [No Abstract] [Full Text] [Related]
14. Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors. Wu Q; Chu Q; Zhang H; Yang B; He X; Zhong Y; Yuan X; Chua MLK; Xie C Cancer Commun (Lond); 2020 Aug; 40(8):374-379. PubMed ID: 32666636 [No Abstract] [Full Text] [Related]
15. Outcome of Parkinson's Disease Patients Affected by COVID-19. Antonini A; Leta V; Teo J; Chaudhuri KR Mov Disord; 2020 Jun; 35(6):905-908. PubMed ID: 32347572 [No Abstract] [Full Text] [Related]
16. SARS-CoV-2 & Covid-19: Key-Roles of the 'Renin-Angiotensin' System / Vitamin D Impacting Drug and Vaccine Developments. Cao Z; Wu Y; Faucon E; Sabatier JM Infect Disord Drug Targets; 2020; 20(3):348-349. PubMed ID: 32370727 [No Abstract] [Full Text] [Related]
17. The COVID-19 XPRIZE and the need for scalable, fast, and widespread testing. MacKay MJ; Hooker AC; Afshinnekoo E; Salit M; Kelly J; Feldstein JV; Haft N; Schenkel D; Nambi S; Cai Y; Zhang F; Church G; Dai J; Wang CL; Levy S; Huber J; Ji HP; Kriegel A; Wyllie AL; Mason CE Nat Biotechnol; 2020 Sep; 38(9):1021-1024. PubMed ID: 32820257 [No Abstract] [Full Text] [Related]
18. Effects of disruption from COVID-19 on antimalarial strategies. Ansumana R; Sankoh O; Zumla A Nat Med; 2020 Sep; 26(9):1334-1336. PubMed ID: 32807937 [No Abstract] [Full Text] [Related]
19. COVID-19 and RAAS blockers: Could Aliskiren be an appropriate option? Şen S; Üresin AY Turk Kardiyol Dern Ars; 2020 Oct; 48(7):631-634. PubMed ID: 33034579 [No Abstract] [Full Text] [Related]